278 related articles for article (PubMed ID: 23361237)
1. Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats.
Tarantola E; Bertone V; Milanesi G; Capelli E; Ferrigno A; Neri D; Vairetti M; Barni S; Freitas I
Eur J Histochem; 2012 Oct; 56(4):e41. PubMed ID: 23361237
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidylpeptidase-IV activity and expression reveal decreased damage to the intrahepatic biliary tree in fatty livers submitted to subnormothermic machine-perfusion respect to conventional cold storage.
Tarantola E; Bertone V; Milanesi G; Gruppi C; Ferrigno A; Vairetti M; Barni S; Freitas I
Eur J Histochem; 2014 Jul; 58(3):2414. PubMed ID: 25308846
[TBL] [Abstract][Full Text] [Related]
3. Altered alkaline phosphatase activity in obese Zucker rats liver respect to lean Zucker and Wistar rats discussed in terms of all putative roles ascribed to the enzyme.
Bertone V; Tarantola E; Ferrigno A; Gringeri E; Barni S; Vairetti M; Freitas I
Eur J Histochem; 2011 Feb; 55(1):e5. PubMed ID: 21556120
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
Mentlein R
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
[TBL] [Abstract][Full Text] [Related]
5. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
6. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
Pederson RA; White HA; Schlenzig D; Pauly RP; McIntosh CH; Demuth HU
Diabetes; 1998 Aug; 47(8):1253-8. PubMed ID: 9703325
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
[TBL] [Abstract][Full Text] [Related]
8. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
9. The metabolic and microcirculatory impact of orthotopic liver transplantation on the obese Zucker rat.
Sun CK; Zhang XY; Zimmermann A; Wheatley AM
Transplantation; 2003 Mar; 75(6):761-9. PubMed ID: 12660498
[TBL] [Abstract][Full Text] [Related]
10. Incretins and microRNAs: Interactions and physiological relevance.
Radbakhsh S; Sathyapalan T; Banach M; Sahebkar A
Pharmacol Res; 2020 Mar; 153():104662. PubMed ID: 31982487
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.
Augstein P; Berg S; Heinke P; Altmann S; Salzsieder E; Demuth HU; Freyse EJ
Diabetes Obes Metab; 2008 Sep; 10(10):850-61. PubMed ID: 17970756
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
13. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.
Hinke SA; Gelling RW; Pederson RA; Manhart S; Nian C; Demuth HU; McIntosh CH
Diabetes; 2002 Mar; 51(3):652-61. PubMed ID: 11872663
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitors and diabetes therapy.
McIntosh CH
Front Biosci; 2008 Jan; 13():1753-73. PubMed ID: 17981665
[TBL] [Abstract][Full Text] [Related]
17. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.
Zarrinpar A; Loomba R
Aliment Pharmacol Ther; 2012 Nov; 36(10):909-21. PubMed ID: 23057494
[TBL] [Abstract][Full Text] [Related]
18. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
19. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma.
Stecca BA; Nardo B; Chieco P; Mazziotti A; Bolondi L; Cavallari A
J Hepatol; 1997 Aug; 27(2):337-45. PubMed ID: 9288609
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Pospisilik JA; Stafford SG; Demuth HU; Brownsey R; Parkhouse W; Finegood DT; McIntosh CH; Pederson RA
Diabetes; 2002 Apr; 51(4):943-50. PubMed ID: 11916911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
